Shots:

• The NMPA has approved the IND application of SPR206 (IV) for the treatment of MDR gram-negative bacterial infections. Everest will initiate the clinical program in China & results from the P-I study is expected in 2022
• Everest got exclusive rights to develop- manufacture & commercialize SPR206 in China- South Korea- and Southeast Asian countries for the same indication under the license agreement with Spero
• Spero has reported the results from its P-I SAD & MAD clinical trial for SPR206 which showed that the therapy is well-tolerated with no evidence of nephrotoxicity at doses within the anticipated therapeutic range for MDR gram-negative bacterial infections

  Ref: PR Newswire | Image: Everest Medicines